IN8bio to Present at TD Cowen 46th Annual Health Care Conference

About this update from In8bio, Inc.

[{"type":"image","alt":"IN8bio, Inc","displaySize":"","headline":null,"caption":"IN8bio, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":149,"url":"https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LM3P9KMIYObIbb2x2kkziw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18","width":300,"height":149}},"lazy":false},{"type":"text","content":"NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET.","length":365,"tagName":"p"},{"type":"text","content":"William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to be held March 2-4, 2026, in Boston, will also include one-on-one investor meetings hosted by members of management.","length":250,"tagName":"p"},{"type":"text","content":"A live webcast and replay link for the TD Cowen conference can be found here, and will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.","length":242,"tagName":"p"},{"type":"text","content":"About IN8bio","length":12,"tagName":"p"},{"type":"text","content":"IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells ...

More updates from In8bio, Inc.